Identification of Prognostic Signature and Gliclazide as Candidate Drugs in Lung Adenocarcinoma

Cheng Yang(Northeast Electric Power University), Xiaofang Che(First Hospital of China Medical University), Dongyao Shi(First Hospital of China Medical University), Xueying Zheng(University of Maryland, College Park), Xuejun Hu(Zoucheng People's Hospital), Yizhe Wang(First Hospital of China Medical University), Xu Han(Health and Family Planning Commission of Sichuan Province), Ximing Wang(Shandong University), Yang Chen(Army Medical University), Bowen Yang(First Hospital of China Medical University), Kezuo Hou(First Hospital of China Medical University), Shiying Tang(First Hospital of China Medical University), Yunpeng Liu(Shenyang Institute of Automation), Jianfei Qi(University of Maryland, Baltimore)
Frontiers in Oncology
June 24, 2021
10.3389/fonc.2021.665276
Cited by 33

Related Papers

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
|Clinical Cancer Research|2018|551
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2022|417
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial
|The Lancet Oncology|2015|412